Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083133 · ClinicalTrials.gov registry record
Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis
A clinical trial, sponsored by Cook County Health.
- Completed
- Registry status
- 496
- Enrollment target
NCT02083133: Completed study, sponsored by Cook County Health.
NCT02083133 is a clinical trial that has completed, run by Cook County Health. The registered enrollment target is 496 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02083133 has completed, sponsored by Cook County Health.
- COMPLETED
- Registry status
- 496 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether the current recommendation for a 50% dose reduction in insulin for diabetic patients with a creatinine clearance (CrCl) ≤15 mL/min or on hemodialysis results in an increased number of hypoglycemic episodes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2017-05-17 |
What the finished NCT02083133 record still lists
NCT02083133 is an observational study that tracks outcomes without assigning an intervention. The registered 496 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02083133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02083133 about?
NCT02083133 is a clinical study titled "Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis". The purpose of this study is to assess whether the current recommendation for a 50% dose reduction in insulin for diabetic patients with a creatinine clearance (CrCl) ≤15 mL/min or on hemodialysis results in an increased number of hypoglycemic episodes.
What is the current status of trial NCT02083133?
This trial is currently completed. The enrollment target is 496 participants. The study started on 2013-10-01. Estimated completion is 2017-05-17.
Who is sponsoring clinical trial NCT02083133?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI